MX2022013391A - Pauta posologica para el tratamiento del cancer. - Google Patents

Pauta posologica para el tratamiento del cancer.

Info

Publication number
MX2022013391A
MX2022013391A MX2022013391A MX2022013391A MX2022013391A MX 2022013391 A MX2022013391 A MX 2022013391A MX 2022013391 A MX2022013391 A MX 2022013391A MX 2022013391 A MX2022013391 A MX 2022013391A MX 2022013391 A MX2022013391 A MX 2022013391A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
azd9833
dosage regimen
inhibitor
Prior art date
Application number
MX2022013391A
Other languages
English (en)
Spanish (es)
Inventor
Gutierrez Pablo Morentin
Eric Todd Gangl
Almeida Camila De
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2022013391A publication Critical patent/MX2022013391A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2022013391A 2020-04-24 2021-04-22 Pauta posologica para el tratamiento del cancer. MX2022013391A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063014914P 2020-04-24 2020-04-24
PCT/EP2021/060589 WO2021214253A1 (en) 2020-04-24 2021-04-22 Dosage regimen for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2022013391A true MX2022013391A (es) 2022-11-30

Family

ID=75728802

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013391A MX2022013391A (es) 2020-04-24 2021-04-22 Pauta posologica para el tratamiento del cancer.

Country Status (12)

Country Link
US (3) US20210330653A1 (cg-RX-API-DMAC7.html)
EP (1) EP4138834A1 (cg-RX-API-DMAC7.html)
JP (1) JP7712955B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230005269A (cg-RX-API-DMAC7.html)
CN (2) CN115443135A (cg-RX-API-DMAC7.html)
AU (1) AU2021260829B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022021141A2 (cg-RX-API-DMAC7.html)
CA (1) CA3179907A1 (cg-RX-API-DMAC7.html)
IL (1) IL297216A (cg-RX-API-DMAC7.html)
MX (1) MX2022013391A (cg-RX-API-DMAC7.html)
TW (1) TWI918645B (cg-RX-API-DMAC7.html)
WO (1) WO2021214253A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024083716A1 (en) * 2022-10-17 2024-04-25 Astrazeneca Ab Combinations of a serd for the treatment of cancer
KR102898494B1 (ko) * 2023-10-04 2025-12-09 삼성전자주식회사 양자점 조성물, 그 제조방법, 그의 경화물, 및 이를 포함하는 표시장치
WO2025085738A1 (en) 2023-10-18 2025-04-24 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and methods of treating disease
WO2025189056A1 (en) 2024-03-08 2025-09-12 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and their use in treating disease

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2416527C (en) 2000-08-10 2009-12-22 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
EP1863810A4 (en) 2005-03-22 2010-03-31 Astrazeneca Ab NEW TETRAHYDRO-1H-PYRIDO [4,3-B] INDOLDERIVATE AS CB1 'RECEPTOR LIGANDS
FR2884252B1 (fr) 2005-04-08 2007-05-18 Aventis Pharma Sa Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90
AR058223A1 (es) 2005-11-25 2008-01-23 Palau Pharma Sa Un comuesto de derivados de pirazoloisoquinolina, un procedimiento para l a preparacion de dicho compuesto y una composicion farmaceutica que comprende dicho compuesto
EP2223925A1 (en) 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
HUE052510T2 (hu) 2009-05-27 2021-05-28 Ptc Therapeutics Inc Módszerek a rák és a nem daganatos állapotok kezelésére
WO2010138695A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating neurofibromatosis
WO2010138659A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating brain tumors
EP3205648A1 (en) 2010-06-10 2017-08-16 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
EP2791132A4 (en) 2011-12-14 2015-08-05 Seragon Pharmaceuticals Inc ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
US10987334B2 (en) * 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
EP3733170A1 (en) 2012-07-13 2020-11-04 Oncternal Therapeutics, Inc. A method of treating androgen receptor (ar) -positive breast cancers with selective androgen receptor modulator (sarms)
AP2015008858A0 (en) 2013-05-28 2015-11-30 Astrazeneca Ab Chemical compounds
BR112015030595A2 (pt) 2013-06-19 2017-07-25 Seragon Pharmaceuticals Inc moduladores de receptor de estrogênio de azetidina e usos dos mesmos
EA031077B1 (ru) 2013-06-19 2018-11-30 Серагон Фармасьютикалз, Инк. Модулятор рецептора эстрогена и его применения
WO2015092634A1 (en) 2013-12-16 2015-06-25 Novartis Ag 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
WO2016097071A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Estrogen receptor modulators and uses thereof
TWI784255B (zh) 2014-12-18 2022-11-21 瑞士商赫孚孟拉羅股份公司 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
CN107406433A (zh) 2014-12-18 2017-11-28 豪夫迈·罗氏有限公司 用于治疗癌症的2,3‑二苯基色烯的衍生物
WO2016174551A1 (en) 2015-04-27 2016-11-03 Pfizer Inc. Anti-estrogenic compounds
MX384605B (es) 2015-04-29 2025-03-14 Radius Pharmaceuticals Inc Combinación de palbociclib y rad1901 para usarse en el tratamiento de cáncer de mama en un sujeto con cáncer positivo a receptor de estrógeno.
JP6768711B2 (ja) 2015-05-26 2020-10-14 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 複素環式エストロゲン受容体モジュレーター及びその使用
EP3312184A4 (en) 2015-06-16 2019-02-27 Jiangsu Hengrui Medicine Co., Ltd. PIPERIDINE DERIVATIVE AND ITS PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF
CN106518768B (zh) 2015-09-15 2021-07-02 江苏恒瑞医药股份有限公司 丙烯酸类衍生物、其制备方法及其在医药上的应用
WO2017059139A1 (en) 2015-10-01 2017-04-06 Olema Pharmaceuticals, Inc. TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS
JP6920295B2 (ja) 2015-11-09 2021-08-18 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト テトラヒドロナフタレンエストロゲン受容体モジュレーター及びその使用
EP3378861B1 (en) 2015-11-12 2021-08-04 Zhejiang Hisun Pharmaceutical Co., Ltd. Acrylic acid derivative, preparation method and use in medicine thereof
WO2017107754A1 (zh) 2015-12-22 2017-06-29 江苏恒瑞医药股份有限公司 苯并哌啶类衍生物、其制备方法及其在医药上的应用
WO2017160990A1 (en) 2016-03-15 2017-09-21 Merrimack Pharmaceuticals, Inc. Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
EP3440067B1 (en) 2016-04-08 2021-05-26 F. Hoffmann-La Roche AG Tetrahydroisoquinoline estrogen receptor modulators and uses thereof
TW201803870A (zh) 2016-04-20 2018-02-01 阿斯特捷利康公司 化學化合物
WO2017192991A1 (en) 2016-05-06 2017-11-09 Xavier University Of Louisiana Selective estrogen receptor down-regulators (serds)
WO2018001232A1 (zh) 2016-06-29 2018-01-04 浙江海正药业股份有限公司 丙烯酸类衍生物及其制备方法和其在医药上的用途
US10149839B2 (en) 2016-07-25 2018-12-11 Astrazeneca Ab Chemical compounds
CN107814798B (zh) 2016-09-14 2020-11-03 四川科伦博泰生物医药股份有限公司 3-取代丙烯酸类化合物及其制备方法和用途
EP3512842B1 (en) 2016-09-15 2024-01-17 Arvinas, Inc. Indole derivatives as estrogen receptor degraders
UA125824C2 (uk) 2016-10-24 2022-06-15 Астразенека Аб 6,7,8,9-ТЕТРАГІДРО-3H-ПІРАЗОЛО[4,3-f]ІЗОХІНОЛІНОВІ ПОХІДНІ, ЗАСТОСОВНІ В ЛІКУВАННІ РАКУ
BR102016024814A2 (pt) 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
WO2018109607A1 (en) 2016-12-16 2018-06-21 Pfizer Inc. Glp-1 receptor agonists and uses thereof
US20200077658A1 (en) 2016-12-16 2020-03-12 Basf Se Pesticidal Compounds
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制RORγ及其他用途的嘧啶三環烯酮衍生物
MX2022004474A (es) 2016-12-16 2023-08-15 Janssen Pharmaceutica Nv Inhibidores de moléculas pequeñas de la familia de quinasas jak.
JP6793836B2 (ja) 2016-12-16 2020-12-02 イーライ リリー アンド カンパニー 変異体idh1およびidh2阻害剤としての7−フェニルエチルアミノ−4h−ピリミド[4,5−d][1,3]オキサジン−2−オン化合物
AR110782A1 (es) 2017-01-30 2019-05-02 Chiesi Farm Spa Derivados de tirosinamida como inhibidores de rho-quinasa

Also Published As

Publication number Publication date
KR20230005269A (ko) 2023-01-09
IL297216A (en) 2022-12-01
TWI918645B (zh) 2026-03-21
CN120267673A (zh) 2025-07-08
US12364689B2 (en) 2025-07-22
CN115443135A (zh) 2022-12-06
US20230248709A1 (en) 2023-08-10
JP2023522415A (ja) 2023-05-30
TW202206073A (zh) 2022-02-16
CA3179907A1 (en) 2021-10-28
WO2021214253A1 (en) 2021-10-28
BR112022021141A2 (pt) 2022-12-06
EP4138834A1 (en) 2023-03-01
JP7712955B2 (ja) 2025-07-24
US20210330653A1 (en) 2021-10-28
AU2021260829A1 (en) 2022-12-15
AU2021260829B2 (en) 2024-01-11
US20250352531A1 (en) 2025-11-20

Similar Documents

Publication Publication Date Title
BR112022021141A2 (pt) Regime de dosagem para o tratamento de câncer
WO2009099634A3 (en) Picoplatin and amrubicin to treat lung cancer
NZ604029A (en) Methods of treating bladder cancer
WO2008012666A3 (en) Treatment and prevention mucositis by anthocyanidin derivatives
ZA202310050B (en) Pharmaceutical composition for preventing or treating fibrosis
CN102046187A (zh) 用于治疗癌症的方法和组合物
BR112014027010A2 (pt) uso de laquinimod de alta dose para tratamento de esclerose múltipla
JOP20220118A1 (ar) طرق لعلاج سرطان الرئة للخلايا الصغيرة بصيغ من لوربينيكتيدين
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
MX2023005078A (es) Nuevas formas cristalinas de un compuesto inhibidor de kras g12c.
AU2016382780A1 (en) Combination of HDAC inhibitor and anti-PD-L1 antibody for treatment of ovarian cancer
NZ801252A (en) Pharmaceutical composition comprising insoluble camptothecin compound-containing nanoparticle for treatment of cancer and combination therapy thereof
NO333189B1 (no) Anvendelse av buprenorfin for fremstilling av en transdermal doseringsform for behandling av medikamentavhengighet, samt sett omfattende slike doseringsformer.
JOP20230219A1 (ar) نظام جرعات سوتوراسيب
JP2023522415A5 (cg-RX-API-DMAC7.html)
MX2023013614A (es) Uso de conjugado farmaco-anticuerpo en combinacion con inhibidor de puntos de control inmunitario en el tratamiento del cancer urotelial.
BRPI0510895A (pt) formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
MX2023005695A (es) Administracion de agonista de sting, inhibidores de puntos de control y radiacion.
BR112022026558A2 (pt) Novo composto e composição farmacêutica para prevenir ou tratar câncer resistente que compreende o mesmo
Izumi et al. CYP3A-mediated drug interaction profile of Bruton tyrosine kinase inhibitor, acalabrutinib
ZA202305383B (en) Topical administration of 2- (diethylamino) ethyl 2- (4-isobutylphenyl) propionate for treatment of diseases
TN2016000179A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor.
CN103596565A (zh) 塞克硝唑在口腔感染治疗中的应用
RASHKIS et al. PROTECTION AGAINST RESERPINE-INDUCED" PARKINSONISM"